OncoSec Medical Inc  

(Public, NASDAQ:ONCS)   Watch this stock  
Find more results for ONCS
2.10
-0.01 (-0.47%)
After Hours: 2.12 +0.02 (0.95%)
Nov 20, 4:35PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.04 - 2.15
52 week 0.88 - 2.95
Open 2.11
Vol / Avg. 1.00M/4.82M
Mkt cap 62.18M
P/E     -
Div/yield     -
EPS -1.06
Shares 29.61M
Beta 2.97
Inst. own 6%
Dec 6, 2017
Q1 2018 OncoSec Medical Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 10, 2017
OncoSec Medical Inc at 2017 Society of Immunotherapy for Cancer Annual Meeting
Oct 25, 2017
Q4 2017 OncoSec Medical Inc Earnings Call
Oct 25, 2017
Q4 2017 OncoSec Medical Inc Earnings Release
Sep 11, 2017
OncoSec Medical Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -134.40% -90.05%
Return on average equity -177.48% -110.71%
Employees 34 -
CDP Score - -

Address

5820 Nancy Ridge Dr
SAN DIEGO, CA 92121-2842
United States - Map
+1-858-2107333 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

Officers and directors

Avtar S. Dhillon M.D. Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Punit S. Dhillon President, Director
Age: 36
Bio & Compensation  - Reuters
Daniel J. O'Connor Esq. Chief Executive Officer, Director
Bio & Compensation  - Reuters
Richard B. Slansky Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Sheela Mohan-Peterson J.D. Chief Legal and Compliance Officer
Age: 54
Bio & Compensation  - Reuters
Sharron Gargosky PhD Chief Clinical and Regulatory Officer
Age: 52
Bio & Compensation  - Reuters
James Michael DeMesa M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Annalisa M. Jenkins Independent Director
Age: 52
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters